Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

Overview
Commercial CAR T cell manufacturing is leaving the open, manual academic bench for closed, automated systems that can scale. This review maps the trade-offs: the five autologous products approved in the U.S. at the time, the cost of running instruments in parallel, allogeneic alternatives and non-viral delivery.
What this paper found
Commercial CAR T cell production is moving from open, manual, academic-style processes toward closed and automated systems that can scale. Five autologous CAR T products were approved in the U.S. as of the review, all using viral vectors. Closed platforms reduce handling but are costly and make one product per instrument, so scaling out needs parallel units. Allogeneic products could instead be scaled up from one donor collection, though they face allo-rejection and shorter persistence. Nonviral and genome-editing delivery, shortened expansion (some protocols use only a few days) and slow sterility testing are discussed, along with GMP staffing, regulatory and decentralized manufacturing questions.
Note: This is a narrative review; the authors note that further studies are needed for several platforms, for example the Quantum system for CAR T cell expansion.
Allogeneic products, however, may become the model of choice for products manufactured at scale in larger centralized commercial facilities once the limitations discussed above can be overcome. — Mohamed Abou-el-Enein, Magdi Elsallab, Steven A. Feldman, Andrew D. Fesnak, Helen E. Heslop, Peter Marks, Brian G. Till, Gerhard Bauer, Barbara Savoldo, Blood Cancer Discovery
Study details
- Authors
- Mohamed Abou-el-Enein, Magdi Elsallab, Steven A. Feldman, Andrew D. Fesnak, Helen E. Heslop, Peter Marks, Brian G. Till, Gerhard Bauer, Barbara Savoldo
- Institution
- Division of Medical Oncology, Department of Medicine, and Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA · Joint USC/CHLA Cell Therapy Program, University of Southern California, and Children's Hospital Los Angeles, Los Angeles, California, USA · Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo Alto, California, USA · Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA · Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA · Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, Texas, USA · Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA · Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA · Institute for Regenerative Cures (IRC), University of California Davis, Sacramento, California, USA · Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
- Journal
- Blood Cancer Discovery
- Year
- 2021
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy
Explore related
Full citation
Abou-El-Enein M, Elsallab M, Feldman SA, et al. Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy. Blood Cancer Discov. 2021;2(5):408-422.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.